Cellectar Biosciences expands iopofosine I 131 collaboration with WARF

Cellectar Biosciences announced a new licensing agreement with the Wisconsin Alumni Research Foundation, WARF, for intellectual property that was the result of collaborative research conducted at the University of Wisconsin-Madison, UW, with iopofosine I 131 in pediatric cancers. Under the terms of the agreement, Cellectar has an exclusive license to develop and commercialize iopofosine in various pediatric solid cancers, such as high-grade glioma, neuroblastoma and sarcoma. “This licensing agreement further strengthens our iopofosine I 131 patent portfolio and our industry leading position in radiopharmaceutical patent grants and applications. It also expands our long-standing relationship with the University of Wisconsin. WARF, the intellectual property management arm of the UW, is highly respected for its longstanding history of successfully protecting intellectual property associated with its license agreements.” said James Caruso, president and CEO of Cellectar. “Based on the encouraging performance of iopofosine in our pediatric Phase 1a study, we were awarded a $2 million NCI grant to further evaluate the activity of iopofosine in pediatric high-grade gliomas with anticipation of first patient enrollment in the near term.”